

WV MEDICAID PAXLOVID BILLING

Attention WV Medicaid Pharmacy Providers,

In October 2023, Pfizer and the US Department of Health and Human Services (HHS), reached an agreement to extend patient access to the COVID-19 oral antiviral medication, Paxlovid, for individuals receiving Medicaid, Medicare and those who are uninsured through the end of 2024. On December 1, 2023, Pfizer launched its US Government Patient Assistance (USG PAP), PAXCESS Patient Support Program. Patients, caregivers, and healthcare professionals, including pharmacists, may enroll patients by visiting: <https://paxlovid.iassist.com/attestation> or calling 877-C19-PACK (877-219-7225).

For dates of service beginning December 28, 2023, all West Virginia Medicaid pharmacy claims for commercially available Paxlovid products will be reimbursed in the same manner as other covered outpatient drugs. The State is eligible for additional manufacturer rebates. For West Virginia Medicaid to be fully reimbursed by Pfizer, 340B claims will **BE REVERSED** if submitted.

COVERED ENTITIES PARTICIPATING IN 340B PROGRAMS SHOULD CONTINUE TO OBTAIN NO-COST PAXLOVID THROUGH THEIR CURRENT CHANNELS OR UTILIZE THE PAXCESS PROGRAM <https://paxlovid.iassist.com/attestation> or call 877-C19-PACK FOR THE WV MEDICAID MEMBERS THEY SERVE.

ANY 340B PHARMACIES BILLING WV MEDICAID FOR PAXLOVID ARE REQUIRED:

1. **TO BILL FROM NON-340B INVENTORY.**

IF NON-340B INVENTORY IS UNAVAILABLE, 340B PHARMACIES MAY:

2. **ACCESS THE PAXLOVID PATIENT ASSISTANCE PROGRAM OR**
3. **FILL PRESCRIPTIONS WITH NO-COST PAXLOVID PROVIDED TO THE COVERED ENTITY.**

FOR QUESTIONS REGARDING PAXLOVID BILLING, PLEASE CONTACT THE GAINWELL PROVIDER SUPPORT DESK AT 1-888-483-0801.

FB 66812272023